Biomarin Pharmaceutical Inc. - Registered Shares
BMRN
Market Cap$11.73B
Close$
$80.20
29% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details
Target Price by Analysts
29% upsideBiomarin Pharmaceutical - Registered Shares Target Price Details$8.10
87% downside
Current Fair Value
87% downsideOvervalued by 87% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $11.73 Billion |
|---|---|
| Enterprise Value | $-69,094,428,010.00 |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $0.89 |
| Beta | 0.31 |
| Outstanding Shares | 190,429,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 36.36 |
|---|---|
| PEG | 0.01 |
| Price to Sales | 0.02 |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | -0.09 |
| Enterprise Value to EBIT | -0.61 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | -8.61 |
| Debt to Equity | 0.11 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Biomarin Pharmaceutical Inc.
CEO: Jean-Jacques Bienaime